In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.

EGPA, previously known as Churg-Strauss syndrome, is a rare inflammatory disorder characterized by asthma, necrotizing ...

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

Fasenra (benralizumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with eosinophilic ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.

Sadly what was the battle to improve my health is now the struggle to protect my vital organs. This is now the fight of my ...

Actress and TV host Kris Aquino returned to the Philippines early Friday morning, after years of seeking treatment for her ...

It is also approved in children and adolescents ages six and above in the US and Japan. EGPA, formerly known as Churg-Strauss Syndrome, is a rare, immune-mediated inflammatory disease that is caused ...

AstraZeneca's Fasenra (benralizumab) has been approved by the US FDA for the treatment of eosinophilic granulomatosis with ...

AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...